Argenica (ASX:AGN) continues on pace for pivotal Australian stroke trials
Pivotal trials which could position an Australian therapeutic as a leading candidate in the fight against stroke continue on pace.
Pivotal trials which could position an Australian therapeutic as a leading candidate in the fight against stroke continue on pace.
Immuron heads toward a third set of Phase 2 clinical studies after pre-clinical success against a deadly infection.
OTC Markets is expected to launch its new OTC Overnight service on its OTCQX and OTCQB markets in early July,…
More preclinical data showing efficacy on an animal model has Argenica further on the path toward clinical trials for traumatic brain injury.
ARG-007 trials will continue unmodified across ten Australian hospitals after no adverse events in the first five patients.
Argenica’s Liz Dallimore on clinical trials, cerebral tribulations, and dosing its first patient in the battle against stroke.
A first dosing marks the official beginning of Phase 2 clinical trials to prove ARG-007’s efficacy in treating victims of acute ischaemic stroke.
A Pediatric Disease Designation for Argenica’s therapeutic opens the post-clinical way for a priority review and path to market.
More positive Travelan results support progression toward Phase 3 clinical trials and a pivotal FDA registration.
Emyria authorised to prescribe MDMA to treat Australian’s with PTSD.